Brent Lang Named to Outset Medical’s Board of Directors

Outset Medical Inc. has appointed medtech veteran Brent D. Lang to its board of directors. Hemost recently served as chairman and CEO of Vocera Communications, a global provider of clinical communication and workflow solutions, until its $3 billion acquisition by Stryker in 2022.
 
“Brent brings a wealth of healthcare expertise to the Outset board, including in growing and scaling software-enabled business models, which is well-aligned with our recurring revenue model,” Outset Medical Board Chair/CEO Leslie Trigg said. “He is an ideal board member to help guide our growth and with a vision to improve the lives of patients that fits perfectly with Outset’s moral mission.”
 
Concurrent with Lang’s appointment, Katie M. Szyman has stepped down from the Outset board to assume leadership of Edwards Lifesciences’ Critical Care spinoff.
 
“As we welcome Brent, we want to also thank Katie for her service to the Outset board during a period of growth and change following our public offering,” Trigg added. “We wish her well as she begins an exciting new phase of her career journey.”
 
Lang will serve on the Outset Medical board’s Audit Committee. He chairs the Movella Holdings Inc. board, a company specializing in movement digitization, and is a member of the Thriveworks board, a private company that provides mental health services. Including his role as chairman/CEO, Lang spent more than 20 years in various leadership positions at Vocera, including president and chief operating officer and vice president of Marketing and Business Development. Earlier in his career, he held various roles at 3Com Corporation, a networking company, and was a strategy consultant for Monitor Company Inc., a consulting firm advising Fortune 500 companies.

Lang earned a bachelor of science degree from the University of Michigan and an MBA from the Stanford University Graduate School of Business. He was also a gold medalist member of the 1988 U.S. Olympic swimming team.
 
“I look forward to joining the board, and a company that is having a direct impact on the lives of dialysis patients and providers,” Lang stated. “The Outset team has surrounded its Tablo platform with a highly differentiated software and service ecosystem that provide clear opportunities for growth well into the future.”
 
Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo Hemodialysis System, cleared by the U.S. Food and Drug Administration for use from the hospital to the home, transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be used across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with two-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical Inc.